Pharma companies on edge over Trump tariff tantrum: ‘Will he, won’t he?’

Indian pharma stocks benefit from the US's 90-day tariff pause, but uncertainty persists about future tariffs affecting generics. Any high tariffs in pharma, particularly for generics, are unlikely to sustain, says Kotak

Markets